1. Introduction {#s0005}
===============

Lysinuric protein intolerance (LPI, OMIM \# 222700) is an autosomal recessive inborn error of metabolism associated with mutations in *SLC7A7*, the gene encoding solute carrier family 7 (amino acid transporter light chain), member 7 [@bb0005], [@bb0010]. This protein binds to solute carrier family 3 (amino acid transporter heavy chain), member 2, to form the heterodimeric *y* + *L* cationic amino acid transporter which transports arginine, lysine, and ornithine at the basolateral membrane of intestinal and renal tubular cells. In LPI, decreased transporter activity results in low plasma lysine, ornithine, and arginine. It has been proposed that patients manifest with clinical symptoms of urea cycle disorders because of deficiencies of urea cycle intermediates within the cellular compartment.

Classically, patients with LPI develop vomiting and diarrhea after introduction of protein-rich foods. Other presenting features may include failure to thrive, protein avoidance, and neurologic symptoms of hyperammonemia such as lethargy, abnormal behavior, and hypotonia after protein-rich meals. Rare presentations include systemic lupus erythematosus [@bb0015], [@bb0020], [@bb0025] or interstitial lung disease [@bb0030]. Long-term complications of LPI may include pulmonary alveolar proteinosis, dyslipidemia, hematologic abnormalities, macrophage activation syndrome, renal disease, and osteoporosis. Treatment involves dietary protein restriction and citrulline supplementation to replete urea cycle intermediates. Oral lysine supplementation and nitrogen-scavenging agents have also been used.

In the present report, we describe a 5-year-old male with short stature and speech delay who was followed for idiopathic osteoporosis and fragility fractures. Whole exome sequencing (WES) with chromosomal microarray analysis (CMA) revealed a diagnosis of LPI, demonstrating that idiopathic osteoporosis should raise suspicion for LPI.

2. Case report {#s0010}
==============

2.1. Clinical description {#s0015}
-------------------------

The patient was born to non-consanguineous parents after an unremarkable 37-week gestation. His birth weight was 3.5 kg (25--50th centile), and length was 50.8 cm (50--75th centile). At 1.5 months of age, he exhibited irritability when weaned from breast milk to infant milk-based formula. These symptoms resolved with transition to another milk-based formula.

The patient had an otherwise uneventful course until 14 months of age, when he developed an intermittent limp and had periods in which he reverted from walking to crawling for a single day. At 22 months of age, he sustained a non-displaced right supracondylar fracture following a witnessed fall. At 24 months of age, he fractured his left distal humeral diaphysis also after a fall.

His fragility fractures prompted a skeletal genetic assessment at 26 months of age. Detailed pedigree analysis revealed that he was the only product of the union between his 22-year-old father (Mexican ancestry) and 19-year-old mother (Mexican/Salvadoran ancestry). There was no family history of fragility fractures, dental anomalies, blue sclera, or hearing loss. Physical examination demonstrated a height of 76.1 cm (less than 5th centile), a weight of 10.3 kg (just below 5th centile), and a head circumference of 49 cm (25th--50th centile). Examination was notable for a depressed nasal bridge, prominent cheeks, tented upper lip, mild limping gait, normal skin texture and elasticity, and absence of blue sclera or contractures. Initial investigations revealed mildly elevated phosphorus, normocytic anemia, and elevated alkaline phosphatase ([Table 1](#t0005){ref-type="table"}). A radiographic skeletal survey suggested osteopenia but no wormian bones ([Fig. 1](#f0005){ref-type="fig"}). Bone age was consistent with chronological age. The second metacarpal cortical thickness measurement at 3 years (height age of 15 months) was 0.5 mm (mean cortical thickness for 1-year-old males is 1.46 mm with standard deviation of 0.30 mm, and for 2-year-old males is 1.85 mm with standard deviation of 0.39 mm) [@bb0035] and, thus, also supported the qualitative assessment of low bone mass on plain radiographs ([Fig. 1](#f0005){ref-type="fig"}). An oligonucleotide CMA (Baylor Medical Genetics Laboratory, Version 8.1) did not reveal any causative copy number variation. *COL1A1* and *COL1A2* sequencing to evaluate for common forms of osteogenesis imperfecta did not identify mutations.

Over the course of the next 14 months, he had 3 additional fractures (distal right femoral metaphysis, distal right radial metaphysis, and left femoral diaphysis), and bisphosphonate therapy (zoledronic acid) was initiated. Two additional fractures (right tibia/fibula, right proximal humerus) occurred within the first year of zoledronic acid therapy, with no additional fractures thereafter. The second metacarpal cortical thickness measured 1 year after initiating therapy (height age of 2 years) was 1 mm (mean cortical thickness for 2-year-old males is 1.85 mm with standard deviation of 0.39 mm and for 4-year-old males is 2.48 mm with a standard deviation of 0.37 mm) [@bb0035]. His short stature persisted with normal growth velocity, and speech delay became apparent between 2 and 3 years of age, prompting further diagnostic evaluation with clinical whole exome sequencing (WES analysis, Baylor Medical Genetics Laboratories) [@bb0040].

2.2. Molecular and biochemical evaluation {#s0020}
-----------------------------------------

A clinical WES demonstrated an apparently homozygous nonsense mutation in *SLC7A7* ([Table 2](#t0010){ref-type="table"}). Sanger sequencing showed that the proband\'s mother was heterozygous for this mutation but did not demonstrate a mutation in the father. This finding raised the possibility of LPI with an undetected deletion within *SLC7A7* on the second allele. A later version CMA with higher exon coverage (Baylor Medical Genetics Laboratories, version 9.1.1) demonstrated a heterozygous 3 Kb deletion involving exons 6 through 11 in *SLC7A7* that was confirmed to be present in the father. Deletions of this region of *SLC7A7* have been previously described in patients with LPI [@bb0045]. Hence, this patient\'s diagnosis of LPI is due to compound heterozygosity for a nonsense mutation and a multi-exon deletion occurring in *trans* in the *SLC7A7* gene. Lysinuria with low plasma levels of ornithine, arginine, and lysine confirmed the diagnosis of LPI. Interestingly, despite persistent lysinuria, the levels of urine arginine and ornithine were normal and have remained normal on repeat analyses ([Table 3](#t0015){ref-type="table"}). Post-prandial plasma ammonia and urine orotic acid were elevated. Serum lactate dehydrogenase and ferritin were also elevated.

A dietary history revealed that he was self-restricted to between 1.2 and 1.8 g/kg of protein per day without post-prandial vomiting or lethargy. This dietary protein restriction was continued, and citrulline supplementation was initiated. Laboratory evaluation six weeks after introduction of citrulline demonstrated normal pre- and post-prandial ammonia. However, after citrulline was briefly discontinued by the family, his ammonia rose to 173 μmol/L, requiring hospitalization for management. The ammonia returned to the normal range after citrulline was restarted.

3. Discussion {#s0025}
=============

3.1. Osteoporosis as a presenting feature of LPI {#s0030}
------------------------------------------------

Multiple fractures and low bone density are unusual presenting features of LPI. To our knowledge, osteoporosis has been reported as the presenting feature in only one other patient [@bb0050]. Unlike our patient who presented with multiple fractures, this previously reported 4-year-old female had a history of only a single fracture [@bb0050]. However, radiographs were consistent with osteopenia, and bone biopsy showed reduced bone volumes [@bb0050]. Like our patient, she did not have typical neurologic symptoms of hyperammonemia after meals [@bb0050]. Despite this, she had vomiting and diarrhea after introduction of table food, and physical examination was notable for hepatomegaly, a characteristic finding in LPI [@bb0050].

Although not typically a presenting feature, osteoporosis and osteopenia are observed in many patients with LPI. A recent case series reported 6 Turkish patients with LPI (age range: 11 to 36 years) who had bone mineral density *Z* scores ranging from − 2.1 to − 5.8 [@bb0055]. Likewise, in a cohort of 9 Italian patients, 2 patients had osteoporosis [@bb0060]. In a study of 29 Finnish patients (age range: 3.7 to 47.9 years), 13 had radiographic signs of osteoporosis [@bb0065]. Fifty-seven fractures were reported in 20 of these patients with the number of fractures per patient ranging from 0 to 7 [@bb0065], [@bb0070]. Most fractures occurred before 15 years of age, and as in our patient, the fractures in childhood were associated with minor trauma [@bb0065]. Interestingly, fractures occurred as frequently in patients with osteoporosis as in patients without radiologic evidence of osteoporosis [@bb0065], [@bb0070].

3.2. Treatment of osteoporosis in LPI {#s0035}
-------------------------------------

The efficacy of recommended therapy for improving the osteoporosis in LPI remains unclear. Although citrulline supplementation resulted in radiographic improvement in bone density in one patient [@bb0050], a 2-year study of 19 patients (age range: 1.9 to 32.7 years) who were treated with citrulline with or without lysine supplementation demonstrated no improvement in osteoporosis [@bb0075]. Bone density was not assessed in a trial of oral lysine supplementation [@bb0080]. There is a single report of the use of alendronate in an 11-year-old female with LPI, with improvement in bone density after one year of therapy [@bb0085]. Zoledronic acid was started in our patient prior to his diagnosis of LPI, and within the first year of therapy, decreased fracture frequency was noted.

3.3. Pathophysiology of osteoporosis in LPI {#s0040}
-------------------------------------------

The mechanism underlying osteoporosis and fractures in LPI is unknown. Low vitamin D and calcium, features not seen in our patient, have been attributed to protein self-restriction [@bb0090]. However, rickets-like changes on radiographs are rare in LPI patients [@bb0065] and were not seen in our patient. The presence of elevated hydroxyproline in serum and urine of LPI patients suggests increased collagen degradation [@bb0070]. Furthermore, the finding of decreased collagen synthesis in patient fibroblasts suggests that the process of collagen turnover may be affected [@bb0070]. Decreased levels of circulating cationic amino acids may also contribute to this potential defect in collagen turnover [@bb0070]. Alternatively, increased nitric oxide may contribute to many of the phenotypes associated with LPI, as patients have elevated plasma nitrate levels, and increased nitrite production has been noted in fibroblasts from patients [@bb0095]. Whether this increased nitric oxide synthesis plays a role in bone homeostasis remains unclear. Of note, exogenous nitrate supplementation has been shown to be beneficial for osteoporosis [@bb0100].

The atypical presentation of our patient raised the possibility that one or more variants in other genes may be modifying the phenotype. We reviewed all exome sequence variants listed in the original clinical and expanded clinical reports for any association with fragility fractures or reduced bone mineral density ([Table 1](#t0005){ref-type="table"}, Supplementary Tables 1 and 2). Our patient carries a heterozygous missense mutation in *PLOD3*, a gene that encodes lysyl hydroxylase 3 (LH3). LH3 is involved in the hydroxylation of lysyl residues and O-glycosylation of hydroxylysyl residues in several types of collagen [@bb0105], and it is plausible that a defect in lysine modification might enhance the bone fragility phenotype caused by defective lysine transport. Compound heterozygous mutations in *PLOD3* have been described in one family with several congenital malformations, including skeletal anomalies and scoliosis, as well as osteoporosis with fragility fractures [@bb0110], but to our knowledge, there is no known association between *PLOD3* heterozygous variants and low bone mineral density. Further review of the literature for loci associated with reduction in bone mineral density did not reveal any additional polymorphic variants that might contribute to our patient\'s predisposition to bone fragility [@bb0115], [@bb0170], [@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0145], [@bb0150], [@bb0155].

3.4. Clinical utility of WES {#s0045}
----------------------------

Another unusual feature of our patient\'s presentation is the isolated lysinuria with normal urine ornithine and arginine levels. These urine amino acid results suggest that the diagnosis of LPI might be missed on urine biochemistry alone, and plasma amino acid analysis should be used to complement urine studies in cases of suspected LPI. Two prior case reports describe patients who initially presented with normal urine levels of dibasic amino acids [@bb0050], [@bb0160]. These reports, in conjunction with the finding of isolated lysinuria in our patient, underscore both the value of DNA-based diagnosis such as WES, and the importance of maintaining a high index of suspicion for LPI, even in the face of non-diagnostic biochemical analysis. This case also supports the inclusion of *SLC7A7* as a *bona fide* low bone mass-causing gene in targeted analyses in the context of sequencing panels [@bb0165].

4. Conclusions {#s0050}
==============

LPI should be considered in the differential diagnosis for osteoporosis and multiple fractures in the setting of short stature, particularly when other features of osteogenesis imperfecta (e.g., blue sclera, wormian bones) are absent. As in our patient, these skeletal features may be the only presenting signs of this rare disorder. Furthermore, this case demonstrates the clinical utility of next-generation WES to diagnose patients with idiopathic severe osteoporosis and, in this case, facilitate initiation of appropriate surveillance studies and treatment.

Appendix A. Supplementary data {#s0055}
==============================

Supplementary Tables
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![Skeletal radiographs. (A) Skull films show no evidence of wormian bones. (B, C) Upper extremity and spine films suggest osteopenia. (D) Left-hand radiograph revealed second metacarpal cortical thickness measuring 0.5 mm prior to zoledronic acid. (E) Left-hand radiograph one year later showed second metacarpal cortical thickness of 1 mm.](gr1){#f0005}

###### 

Metabolic bone laboratory values before and after zoledronic acid therapy.

  Laboratory                  Initial value    Normal range      After therapy   Normal range
  --------------------------- ---------------- ----------------- --------------- -----------------
  Calcium, total              8.6 mg/dL        8.6--10.2 mg/dL   9.0 mg/dL       8.8--10.1 mg/dL
  Phosphorus                  5.0 mg/dL        2.5--4.5 mg/dL    5.1 mg/dL       3.1--6.3 mg/dL
  Alkaline phosphatase        293 U/L          40--115 U/L       319 U/L         134--346 U/L
  Vitamin D, 25-hydroxy       43 ng/mL         30--100 ng/mL     30 ng/mL        ≥ 20 ng/mL
  Vitamin D, 1,25-dihydroxy   173 pg/mL        31--87 pg/mL                      
  PTH, intact                 78 pg/mL         NE                46 pg/mL        NE
  Osteocalcin                 31 ng/mL         9--38 ng/mL       56 ng/mL        39--121 ng/mL
  Collagen N-telopeptide      \< 10 nm BCE/L   NE                                
  Collagen C-telopeptide                                         422 pg/mL       574--1849 pg/mL

NE---not established; PTH---parathyroid hormone.

###### 

Whole exome sequence results.

  Disease                                         Inheritance   Gene        Nucleotide   Amino acid   Zygosity   Novel
  ----------------------------------------------- ------------- ----------- ------------ ------------ ---------- -------
  *Class: Damaging*                                                                                              
  Lysinuric protein intolerance \[MIM:222700\]    AR            *SLC7A7*    c.1122C\>A   p.C374X      Hom        Yes
                                                                                                                 
  *Class: VUS*                                                                                                   
  Lysyl hydroxylase 3 deficiency \[MIM:612394\]   AR            *PLOD3*     c.1030G\>A   p.A344T      Het        No
  Wolcott-Rallison syndrome \[MIM:226980\]        AR            *EIF2AK3*   c.2286G\>T   p.Q762H      Het        Yes

AR---autosomal recessive; Het---heterozygous; Hom---homozygous; VUS---variant of unknown clinical significance.

###### 

Biochemical evaluation.

  Laboratory              Initial result      With therapy   Discontinued therapy[a](#tf0005){ref-type="table-fn"}   Normal range
  ----------------------- ------------------- -------------- ------------------------------------------------------- ----------------------
  Urine protein           1 +                 Negative                                                               Negative
  Serum LDH                                   2067 U/L                                                               470--900 U/L
  Ferritin                                    248 ng/mL                                                              10--60 ng/mL
  Pre-prandial ammonia    38 μmol/L           25 μmol/L                                                              22--48 μmol/L
                                                                                                                     
  *Post-prandial*                                                                                                    
  Ammonia                 78 μmol/L           25 μmol/L      173 μmol/L                                              22--48 μmol/L
  Urine orotic acid       206.9 mmol/mol Cr                                                                          0.3--2.8 mmol/mol Cr
  Acylcarnitine profile   Normal                                                                                     
                                                                                                                     
  *Plasma amino acids*                                                                                               
  Lysine                  19 μmol/L                          35 μmol/L                                               41--225 μmol/L
  Arginine                7 μmol/L                           3 μmol/L                                                18--127 μmol/L
  Ornithine               5 μmol/L                           3 μmol/L                                                5--100 μmol/L
  Glutamine               1227 μmol/L                        1271 μmol/L                                             266--746 μmol/L
  Glycine                 270 μmol/L                         384 μmol/L                                              92--346 μmol/L
  Alanine                 392 μmol/L                         1499 μmol/L                                             103--528 μmol/L
                                                                                                                     
  *Urine amino acids*                                                                                                
  Lysine                  3874 μmol/g Cr                     1931 μmol/g Cr                                          8--557 μmol/g Cr
  Arginine                59 μmol/g Cr                       27 μmol/g Cr                                            0--117 μmol/g Cr
  Ornithine               9 μmol/g Cr                        10 μmol/g Cr                                            0--170 μmol/g Cr

Cr---creatinine; LDH---lactate dehydrogenase.

Patient discontinued therapy.
